N-Zyme Biomedical

N-Zyme Biomedical has developed a novel class of pepsin inhibitor therapies targeting LPR and GERD. Their lead program, NZYM-001, uses a repurposed HIV protease inhibitor formulated as an oral suspension and dry powder inhaler to locally inhibit pepsin activity. The company’s approach leverages existing safety data to accelerate clinical development. A Phase II proof-of-concept trial for their proprietary sustained-release oral fosamprenavir sodium alginate formulation will begin enrollment in Spring 2025. An IND has been approved by the FDA for a related study at the Medical College of Wisconsin using standard fosamprenavir/Lexiva.